curriculum vitae nora e. sarvetnick vitae – nora e. sarvetnick university of nebraska medical...
TRANSCRIPT
Curriculum Vitae – Nora E. Sarvetnick
University of Nebraska Medical Center
Durham Research Center II, Room 6071
Omaha, NE 68198-5965
Work Ph.: (402) 559-6735
Home Ph.: (402) 885-8141
Fax: (402) 559-7521
Email: [email protected]
Education and Training
1974-1978 Sarah Lawrence College, Bronxville, N.Y.
Bachelor of Arts 6/78 – Choreography emphasis
1976-1977 London University
Junior year abroad – microbial Genetics
1978-1980 Research Assistant with Dr. Ahmad Bukhari, Cold Spring Harbor Laboratory
Genetics of Bacteriophage Mu Transposition
1980-1986 Cold Spring Harbor Laboratory, State University of New York at Stony brook
Department of Biochemistry
Graduate Advisor: Joe Sambrook, PhD awarded June 1986,
“Developmental Genetics of Mouse t Haplotypes”
Post-degree Training
1986-1990 MDA Postdoctoral Fellow
Genentech, Inc.
Academic Appointments
2010-Present Director, Holland Regenerative Medicine Program
University of Nebraska Medical Center
2008-Present Research Director, Department of Surgery-Transplant
University of Nebraska Medical Center
2008-Present Professor, Department of Surgery
University of Nebraska Medical Centre
2000-2008 Professor, Department of Immunology
The Scripps Research Institute
1996-2000 Associate Professor with Tenure, Department of Immunology
The Scripps Research Institute
1994-1996 Associate Professor, Department of Neuropharmacology
The Scripps Research Institute
1990-1994 Assistant Professor, Department of Neuropharmacology
The Scripps Research Institute
Grant Support
Current NIH Grant Support
R01 DA032513-01 Methamphetamine and HIV: Defective immunity with CD8 T cell dysfunction.
Dual PI: Nora Sarvetnick, Total Cost: $2,589,486, 07/15/2011-07/31/2016
U01 AI102012-01 Cytokine receptor populations in human autoimmune diabetes
PI: Nora Sarvetnick, Total Cost: $2,691,311, 07/01/2012-06/30/2017
GSDGAP CytOF discrimination of cell populations
PI: Nora Sarvetnick, Total Cost: $259,875, 06/01/2013-02/28/2015
Other Grant Support
JDRF Biomarkers of Progression in the at-risk setting for Type 1-diabetes
PI: Nora Sarvetnick, Total Cost: $500,000, 04/01/2014-06/30/2016
University of Nebraska Foundation
Kill the Killer Cells
PD/PI: Nora Sarvetnick, Total Cost: $431,983, 2008-2014
Previous NIH Grant Support at PI
P01 AI039664 Proliferative Response of Antigenic Target Cells
P01 DK057644 Regulation of cytokine and CD8 responses in NOD mice
P01 HL048728 Transgenic Mouse Core
P30 MH062261 Immunological Assay Core
R01 AI042231 Mechanism of Coxsackie virus Mediated Auto reactivity
R01AI064325 Mechanistic insights into B7Co-stimulation
R01 DK054063 Counter-regulation in Tissue
R01 DK055230 Islet Progenitor Cells
R01 DK060746 Purification & Characterization of Islet Progenitors
R01 HD029764 Model of Islet Regeneration and Neogenesis
R01 HL062122 Involvement of Nef in Lung Pathogenesis in AIDS
R01 MH063431 Consequences of Nef Expression on CNS Pathology
R13 AI049204 FASEB Research Conference on: Autoimmunity
R21 AI059619- Immunoregulation of Flavivirus Infection
R21 AI063614 Functional Tolerance to Islet Allografts
R21 DK066511 Engraftment of Pancreatic Progenitors
R56AI0940112 Are IL-18 receptor-bearing CD8 T cells pathogenic in human T1D?
U19 AI051973 Role of CD40L in Diabetes In NOD Mouse
U19 AI051973 Genetic Immunization of NOD Mice
Previous Grant Support
University of Nebraska Foundation
Study of genetic and immunological features associated with Type I (insulin-
dependent) diabetes mellitus
PI: Nora Sarvetnick, Total Cost: $100,000, 2011-2013
US Patents Awarded
6,242,666 Animal model for identifying a common stem/progenitor to liver cells and
pancreatic cells
6,541,251 Pancreatic progenitor 1 gene and its uses
6,753,153 Markers for identification and isolation of pancreatic islet alpha and beta
progenitors
6,911,533 Pancreatic progenitor 1 gene and its uses
Consulting and Advising Positions
Scientific Advisory Boards
1994-1999 Neocrine Inc.
1998-2001 Stem Cells
1999-2004 NIAID, Tolerance Network Assay Development Committee
2004-Present Larry Hillblom Foundation
2012-Present UNMC, Tissue Science Facility
Current Post-Doctoral Trainees and Junior Faculty
2012-Present Shakeel Mir, PhD, Research Associate
University of Nebraska Medical Center
2008-Present Robert Harms, MA, Research Associate
University of Nebraska at Omaha
2009-Present Nick George, PhD, Postdoctoral Fellow/Research Associate
University of Nebraska Medical Center
2010-Present Brian Boerner, MD, Assistant Professor
University of Nebraska Medical Center
Past Post-Doctorals and Trainees
1991-1993 Lise Wogensen-Bach, M.D. University of Copenhagen, Denmark. Funded
by fellowships from Juvenile Diabetes Foundation and Danish Medical
Research Council. Currently: Assistant Professor, University of Aarhus,
Denmark.
1993-1994 Kathrin Geiger, M.D., Ph.D. Universitat Frankfurt, Germany. Funded by a
postdoctoral fellowship from the DFG (Viral pathogenesis in cytokine
transgenic mice). Currently: Associate Professor, Depts. Opthomology and
Neuropathology Neurologisches Institut Universitat Frankfurt, Frankfurt,
Germany.
1991-1995 Danling Gu, M.D. Zhanjiang Medical College, China. Funded by fellowships
from the Myasthenia Gravis Foundation and the Juvenile Diabetes Foundation
(Pancreatic islet growth and development). Currently: Scientist II at Selective
Genetics Gene Therapeutics, San Diego, California.
1992-1995 Myung-Shik Lee, M.D., Ph.D. Seoul National University, Korea. Funded by a
fellowship from the Multiple Sclerosis Society (IFN-g viral antigen interactions).
Currently: Assistant Professor at Samsung Medical Center Seoul, Korea.
1995-1996 Roberto Gianani, M.D. University of Rome, Endocrinology and Metabolic
Diseases, Rome, Italy. Viruses, cytokines, antigens and autoimmunity.
Currently: Department of Pathology, University of Colorado, Denver, Colorado.
1995-1996 Katsunori Nonogaki, M.D., Ph.D. University of California, San Francisco.
Cytokine regulation of obesity. Currently: University of California, San
Francisco
1994-1997 Regula Mueller, Ph.D. University of Basel, Basel, Switzerland. Funded by
Swiss National Fellowship and the Advanced Swiss National Foundation
Fellowship. Currently: Clinical Research Associate at PharmaPart AG in
Zuerich, Switzerland.
1995-1997 Ellene Jones, Ph.D. University of Texas Southwestern Medical Center Dallas,
Texas. Previously funded by NIH fellowship. Currently: Rsch. Assoc,
University of Maryland.
1997-1998 Li-Karine Schiotz, University of Aarhus. Funding Danish MRC. Former
Graduate Student Currently: Post-doctoral research studies at the University
of Aarhus
1996-1997 Li Xu, Ph.D. University of Texas Austin, Texas. Funded by a training grant,
currently: Scientist I at Maxygen in Santa Clara, CA.
1996-1999 Scott Gallichan, Ph.D. McMaster University, Ontario Canada. Funded by
American Diabetes Association Fellowship and Juvenile Diabetes Foundation
International. Currently: Senior Scientific Associate, McMaster University,
Ontario Canada.
1996-1999 Marika Falcone, M.D., Ph.D. Albert Einstein College of Medicine, Bronx, NY.
Funded by fellowships from Myasthenia Gravis and Juvenile Diabetes
Foundation International Fellowship. Currently: Assistant Professor HSR
Research Institute, Via Olgettina 60 20132, Milan, Italy
1997-2000 Michelle Krakowski, Ph.D. Montreal Neurological Institute & Hospital,
Montreal Quebec, Canada. Funded by National Multiple Sclerosis Society.
(Role of IL-10 & CD8 T cells in MS). Currently: Scientist, Pharmingen, Inc.,
San Diego, CA.
1995-2000 Balaji Balasa, Ph.D. Memorial University of Newfoundland. Myasthenia
Gravis Foundation Fellowship & Juvenile Diabetes Foundation, (awarded
sequentially) (Immunomodulation of autoimmune diabetes via genetic
immunization of NOD mice with DNA vectors expressing islet antigen &
costimulatory molecules). Currently: Staff Scientist, Protein Design Labs, Inc.
Fremont, CA.
1998-2001 Antonio La Cava, M.D., Ph.D. Federico II, University of Naples, Italy. Funded:
Juvenile Diabetes Foundation International (Dissection of the genetic basis for
cytokine-mediated immunoprotection & acceleration of insulin-dependent
diabetes mellitus.) Currently: Assistant Professor, UCLA.
1996-2000 Joanna Davies, Ph.D. University of California, San Diego. Funding: NIH and
Novartis. Assistant Professor. Currently: Associate Professor Torrey Pines
Institute for Molecular Studies, San Diego, CA.
1999-2002 Fu Dong Shi, M.D., Ph.D. Karolinska Institute, Stockholm, Sweden. Funding:
Muscular Dystrophy Association Fellowship (The innate immune pathways in
the pathogenesis of myasthenia gravis). Currently: Research Associate,
Scripps Research Institute, Molecular & Experimental Medicine.
1996-2002 Linda Bradley, Ph.D. University of California, San Diego (Funding: NIH grant)
Assistant Professor. Currently: Associate Professor, Sidney Kimmel Cancer
Center, San Diego, CA.
1998-2002 Syamasundar Pakala, Ph.D. School of Biosciences, Jamia Millia Islamia,
Delhi, India. (Counter Regulation in Tissues) Currently: La Jolla Institute of
Allergy and Immunology, La Jolla, CA.
1996-2003 Marc Horwitz, Ph.D. The Scripps Research Institute. Funded by ADA (The
mechanism of coxsackie virus-mediated autoimmune diabetes). Currently:
Microbiology & Immunology Dept., University of British Columbia.
1999-2003 Soon Ha Kim, Ph.D. Seoul National University College of Medicine, Seoul
Korea. Funding: Myasthenia Gravis Fellowship (Role of chemokines &
chemokine receptors in the pathogenesis of myasthenia gravis). Currently:
Research Associate, Scripps Research Institute, Molecular & Experimental
Medicine.
1998-2003 Malin Flodstrom, Ph.D. University of Uppsala, Sweden Funded by JDFI
Advanced Postdoctoral Fellowship, (Are anti- -
cell survival during viral infection?). Currently: Assistant Professor, The
Karolinska Institute, Sweden.
2001-2004 Valeria Judkowski, Ph.D. University of Buenos Aires, Argentina. Currently:
Staff Scientist, Centre d'Immunologie de Marseille-Luminy, Marseille, France.
1996-2004 Cecile King, Ph.D. Institute for Child Health Research, Western Australia
(Funding: JDFI Advanced Postdoctoral Fellowship). Currently: Senior
Research Fellow, Arthritis and Inflammation Program, Garvan Institute of
Medical Research, Darlinghurst, Australia.
2000-2004 Ayse Kayali, Ph.D. University of California, San Diego. Currently: Staff
Scientist, The Islet Research Laboratory, Whittier Institute for Diabetes,
Department of Pediatrics, School of Medicine, University of California, San
Diego.
2002-2004 Yingjie Si, M.D, PhD Schepens Eye Research Institute & Harvard Medical
School, Boston, MA.
2003-2004 Prasanta Maiti, Ph.D. Dept. of Immunology, Weizmann Institute of Science,
India.
1999-2005 Guoxun Liu, MS., M.D. Hospital of Guangdong Medical College, P.R.China,
Currently: Staff Scientist, Genomics Institute of the Novartis Research
Foundation, San Diego, California.
2002-2005 Hyun-Bae Jie, Ph.D. Finch University of Health Sciences, The Chicago
Medical School, Chicago, IL. Currently: Assistant Professor, Department of
Pediatrics, Stanford University.
2003-2005 Wenyuan Wu, M.D. Dept. of Laboratory Medicine, Shenzhen People’s
Hospital, P.R. China, Currently: Senior Research Associate, TSRI,
Department of Immunology, Edgington Laboratory.
2002-2005 Michelle Solomon, Ph.D. Australian National University, Division of
Immunology and Genetics, Canberra, Act, Australia (Funding: JDRF
Postdoctoral Fellowship) Currently: Staff Scientist, Arenas Pharmaceuticals,
La Jolla CA.
2000-2005 Natasha Hill, Ph.D. University of Oxford, United Kingdom. Assistant Professor,
Kings Hospital, London, UK.
2002-2005 Sandrine Arnaud-Dabernat, Ph.D. Assistant Professor, Laboratoire de
Biologie, Differenciation et du Development, Bordeaux, France.
2001-2007 Deepak Yadav, Ph.D. Sr. Research Associate, UCSD, La Jolla, California.
2003-2008 Hong Hua, Ph.D. Institute of Medical Science, School of Graduate Studies,
University of Toronto, Canada. Currently: Sr. Scientist, Johnson & Johnson, La
Jolla, CA.
2001-2008 You-Qing Zhang, M.D., Ph.D. Inst. Of Molecular & Cellular Regulation, Gunma
University, Maebashi, Japan (Funding: Chrohn’s & Colitis Foundation of
America Carreer Development Award).
2005-2008 Shrimati Datta, Ph.D. University of California, Irvine, Department of Biological
Sciences, Irvine California, USA. (Funding: Larry L. Hillblom Foundation,
Postdoctoral Fellowship).
2005-2008 Xiangli Li, Ph.D. School of Public Health and School of Medicine, University
of North Carolina at Chapel Hill, USA. (Funding: Arthritis Foundation,
Postdoctoral Fellowship).
2006-2008 Amir Sabouri, M.D., Ph.D. Kagoshima University Graduate School of Medical
& Dental Sciences, Kagoshima, Japan (Myasthenia Gravis Foundation of
America, Postdoctoral Fellowship).
2009-2010 Vinee Purohit PhD Graduate Student, University of Nebraska Medical Center.
2008-2011 Kyung Soo Kim, PhD Scientific Associate, University of Australia, Melbourne.
1997-2011 Marcie Kritzik, Ph.D., Scientific Associate, University of California, Berkeley.
2004-2011 Annette Marleau, Ph.D. Department of Microbiology and Immunology,
University of Western Ontario, London, Ontario, Canada. (Funding: Larry L.
Hillblom Foundation, Postdoctoral Fellowship).
2010-2012 Matt Wheeler, MD, Research Surgery Resident, University of Nebraska
Medical Center.
2010-2012 Virginia Hardie, MD, Research Surgery Resident, University of Nebraska
Medical Center.
2012-2013 Kamiya Mehla, PhD, Research Associate, University of Nebraska Medical
Center.
Editorial Boards
1994-2000 American Journal of Physiology
Annually Lessons in Animal Models of Diabetes
1996-2010 European Cytokine Network
1998-2003 Diabetes
1999-2004 Diabetologia
1999-2004 Immunology Today
2000-2005 Journal of Immunology, Associate Editor
2008-2014 Cellular Immunology, Editor-in-chief
Books and Publications Edited
Molecular Biology Intelligence Unit: Pancreas Regeneration, R.G. Landes Company
Cytokines and Autoimmune Diseases, Humana Press Inc.
Current Opinion of Immunology, Volume 9, 1998
Grant Reviews
1992-Present JDF Medical Review Committee: Research and Postdoctoral Grants
1994-1995 Chair: Immunogenetics Section, JDF Medical Review Committee
1993-1995 NIH: Consultant and program project committees
1996 NIH: Diabetes Endocrine Research Center -Review committee
1995-1999 Arthritis Foundation Review Committee
Ad Hoc NIMH AIDS study section
1996 NIH: Small Business (STTR)
1997-1998 NIH: Special Emphasis Panel - Review committee
1997-2001 NIH: Immunological Sciences, Study section - Member
Ad Hoc MRC Australian
Ad Hoc MRC United Kingdom
2012 NIH: NIDDK R01 Reviewer
2013 NIH: HAI Reviewer
Current NIH: Special Emphasis Panels
Manuscript Reviews (Most Frequent Journals)
Autoimmunity
Development
Diabetes
Endocrinology
Journal of Clinical Investigation
Journal of Experimental Medicine
Journal of Immunology
Immunity
Cell
Nature
Nature Medicine
Science
Gastroenterology
Awards
1986-1988 Postdoctoral Fellowship from the Muscular Dystrophy Association
1990-1993 Career Development Award from the Juvenile Diabetes Foundation
1995-2000 Principal Investigator, Multidisciplinary Diabetes Program Project Award from
the Juvenile Diabetes Foundation
1996-1999 ADA Mentor Fellowship Award
1999-2003 ADA Mentor Fellowship Award
2005-2009 ADA Mentor Fellowship Award
2008-2009 ADA Mentor Based Fellowship Award
2008-Present J.W. Kieckhefer Foundation
Peer-Reviewed Original Research Publications
1. Chaconas, G., Harshey, R.M., Sarvetnick, N., Bukhari, A.I. (1981) Predominant end-products of prophage
Mu DNA transposition during the lytic cycle are replicon fusions. Journal of. Molecular Biology, 150(3):341-
359.
2. Chaconas G., Harshey, R.M., Sarevetnick, N., Bukhari, A.I. (1981) Mechanism of bacteriophage Mu DNA
transposition. Cold Spring Harbor Symposium Quantitative Biology, Cold Spring Harbor Press pp. 311-322.
3. Sarvetnick, N., Fox, H.S., Mann, E., Mains, P.E., Elliott, R.W., Silver, L.M. (1986) Nonhomologous pairing in
mice heterozygous for a t haplotype can produce recombinant chromosomes with duplications and deletions.
Genetics, 113(3):723-734.
4. Sarvetnick, N., Liggitt, D., Pitts, S.L., Hansen, S.E., Stewart, T.A. (1988) Insulin-dependent diabetes mellitus
induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. Cell, 52(5):773-782.
5. Sarvetnick, N., Tsai, J.Y., Fox, H., Pilder, S.H., Silver, L.M. (1989) A mouse chromosome 17 gene encodes
a testes-specific transcript with unusual properties. Immunogenetics, 30(1):34-41.
6. Sarvetnick, N., Shizuru, J., Liggitt, D., and Stewart, T. (1989) Inflammatory destruction of pancreatic beta
cells in gamma-interferon transgenic mice. Cold Spring Harbor Symposium Quantitative Biology, Cold Spring
Harbor Press pp. 837-842.
7. Bibbins, K.B., Tsai, J.Y., Schimenti, J., Sarvetnick, N., Zoghbi, H.Y., Goodfellow, P., Silver, L.M. (1989)
Human homologues of two testes-expressed loci on mouse chromosome 17 map to opposite arms of
chromosome 6. Genomics, 5(1):139-143
8. Sarvetnick, N., Fox, H. (1990) IFN- and the sexual dimorphism of autoimmune disease. Molecular Biology
Medicine, 7(4):323-331.
9. Sarvetnick, N. (1990) Transgenic Models of Diabetes. Current Opinion in Immunology, 2(4):604-606.
10. Sarvetnick, N., Shizuru, J., Liggitt, D., Martin, L., McIntyre, B., Gregory, A., Parslow, T., Stewart, T. (1990)
Loss of pancreatic islet tolerance induced by beta-cell expression of IFN Nature, 346:844-847.
11. Sarvetnick, N. (1991) Transgenic Mouse Models for Growth Factor Studies. Methods in Enzymology,
198:519-525.
12. Sarvetnick, N. (1991) IFN-g Expressed in Pancreatic Beta Cells- A review of the induced Pathology. LAD III:
Lessons from Animals Diabetes (E. Shafrir, Ed.) Smith Gordon, New York.
13. Sarvetnick, N. (1991) Transgenic Mouse Models for Growth Factor Studies In: Methods in Enzymology,
Academic Press, Inc. 198:519-525.
14. Grodsky, G.M., Cullen, B., Ma, M., Sarvetnick, N. (1991) Characteristics of Insulin Secretion from the
perfused pancreas of diabetic transgenic mice expressing MHC class II in their beta cells. LAD III: Lessons
from Animal Diabetes (E Shafrir, Ed.) Smith Gordon, NY.
15. Shizuru, J., Sarvetnick, N. (1991) Transgenic models of Diabetes Mellitus.(1991) Trends in Endocrinology
& Metabolism, 3:97-104.
16. Weatherall, D., Sarvetnick, N., Shizuru J.A. (1992) Genetic control of Diabetes Mellitus Diabetologia,
35(2):1-7.
17. Lee, M-S., Sarvetnick, N. (1992) Transgenes in Autoimmunity. Current Opinion in Immunology, 4(6):723-
727.
18. Grodsky, G.M., Ma, Y.H., Cullen, B., Sarvetnick, N. (1992) Effect on insulin production sorting and secretion
by major histocompatibility complex class II gene expression in the pancreatic beta-cell of transgenic mice.
Endocrinology, 131(2):933-938.
19. Wogensen, L, Sarvetnick, N. (1992) Cytokines and type 1 diabetes. Clinical Applications of Cytokines. (A
Gearing, J Rossio, J Oppenheim, Eds.) Oxford University Press, NY pp.123-127.
20. Sarvetnick, N, Gu, D-L. (1992) Regeneration of pancreatic endocrine cells in interferon-gamma transgenic
mice. In: Pancreative Islet Cell Regeneration and Growth, (AI Vinik, Ed.) Plenum Press, NY 321:85-94.
21. Gu, D., Sarvetnick, N. (1993) Epithelial cell proliferation and islet neogenesis in IFN- transgenic mice.
Development, 118(1):33-46.
22. Sarvetnick, N., Gurushanthaiah, D., Han, N., Prudent, J., Shultz, P., Lerner, R. (1993) Increasing the
chemical potential of the germline antibody repertoire. Proceedings of the. National Academy of Sciences.
(USA), 90(9):4008-4012.
23. Lee, M-S, Sarvetnick, N. (1993) Transgenic animals: Contribution of transgenic constructs to the etiology
and the pathogenesis of diabetes. (E. Shafrir, Ed.) Annual review of advances in the research of animal’s
diabetes. Smith Gordon, New York, pp. 241-246.
24. Sarvetnick, N. (1993) Islet tolerance in humans and transgenic mice. Molecular Mechanisms of
Immunological Self Recognition. (H. Vogel., Ed.) Academic Press, San Diego, CA, pp.183-186.
25. Wogensen, L., Huang, X., Sarvetnick, N. (1993) Leukocyte extravasation into the pancreatic tissue in
transgenic mice expressing Interleukin 10 in the islets of Langerhans. Journal of Experimental Medicine,
178(1):175-185.
26. Wogensen, L., Ma, Y.H., Grodsky, G.M., Robertson, R.P., Burton, F., Sutcliffe, J.G., Sarvetnick, N. (1993)
Functional effects of transgenic expression of cholera toxin in pancreatic beta cells. Molecular Cell
Endocrinology, 98(1):33-42.
27. Wogensen, L., Lee, M-S., Sarvetnick, N. (1994) Production of interleukin 10 by islet cells accelerates
immune-mediated destruction of beta cells in nonobese diabetic mice. Journal of Experimental Medicine,
179(4):1379-1384.
28. Geiger, K., Howes, E., Gallina, M., Huang, X.J., Travis, G.H., Sarvetnick, N. (1994) Transgenic mice
expressing IFN- in the retina develop cellular inflammation of the eye and photoreceptor loss. Investigative
Ophthalmology Visual Sciences, 35(6):2667-2682.
29. Lee, M-S., Wogensen, L., Shizuru, J., Oldstone, M., Sarvetnick, N. (1994) Pancreatic islet production of
murine interleukin-10 does not inhibit immune mediated tissue destruction. Journal of Clinical Investigation,
93(3):1332-1338.
30. Lee, M-S., Sarvetnick, N. (1994) Induction of vascular addressins and adhesion molecules in the pancreas
of Interferon- transgenic mice. Journal of Immunology 152(9):4597-4603.
31. Gu, D., Lee, M.S., Krahl, T., Sarvetnick, N. (1994) Transitional cells in the regenerating pancreas.
Development, 120(7):1873-1881.
32. Wogensen, L., Molony, L., Gu, D., Krahl, T., Zhu, S., Sarvetnick, N. (1994) Postnatal anti-interferon-
treatment prevents pancreatic inflammation in transgenic mice with beta-cell expression of interferon. Journal
of Interferon Research, 14(3):111-116.
33. Geiger, K., Howes, E.L., Sarvetnick, N. (1994) Ectopic expression of IFN- in the eye protects transgenic mice
from intraocular HSV-1 infections. Journal of Virology, 68(9):5556-5567.
34. Geiger, K., Sarvetnick, N. (1994) Local production of IFN- abrogates the intraocular immune privilege in
transgenic mice and prevents the induction of ACAID. Journal of. Immunology. 153(11):5239-5246.
35. Gu, D-L, Sarvetnick, N. (1994) Murine Transgenic Models of IDDM. Molecular Biology of Diabetes (B.
Draznin and D. LeRoith , Eds.) Humana Press, Inc. 35-47.
36. Lee, M-S, Sarvetnick, N. (1994) Immunological Studies Utilizing Cytokine Transgenic Mice. Transgenesis
and Targeted Mutagenesis in Immunology (Bluethmann, Ed.) Academic Press, Inc. pp. 175-182.
37. Gu, D-L, Sarvetnick, N. (1994) A transgenic model for studying islet development. Advances in Hormone
Research. (C.W. Bardin, Ed.) Academic Press, Vol. 49:161-165.
38. Geiger, K, Sarvetnick, N. (1994) MHC Class I Expression Contributes to the Development of Cataract in
Transgenic Mice With Ectopic Expression of IFN-g. Advances in Ocular Immunology (Nussenblatt RB,
Whitcup, SM, Caspi, RR and Gery I, Eds.) Elsevier Science Publishers, The Netherlands. pp. 135-138.
39. Lee, M-S, Sarvetnick, N. (1994) IL-10 Transgenic Mice. Molecular Biology Intelligency Unit Book Series on
IL-10 (J.E. de Vries and R de Waal Malefyt, Eds.) Landes Publishing Company, Austin, TX, pp. 135-139.
40. Gu, D-L., Wogensen, L., Calcutt, N.A., Xia, C., Zhu, S., Merlie, J.P., Fox, H.S., Lindstrom, J., Powell, H.C.,
Sarvetnick, N. (1995) Myasthenia Gravis-like syndrome induced by expression of interferon-gamma in the
neuromuscular junction. Journal of Experimental. Medicine, 181(2):547-557.
41. Mueller, R., Sarvetnick, N. (1995) Transgenic/knockout mice – tools to study autoimmunity. Current Opinions
in Immunology, 7(6):799-803.
42. Lee, M.S., von Herrath, M., Reiser, H., Oldstone, M.B., Sarvetnick, N. (1995) Sensitization to self (virus)
antigen by In situ expression of Interferon-. Journal of Clinical Investigation, 95(2):486-492.
43. Dai, Y., Schwarz, E.M., Gu, D., Zhang, W.W., Sarvetnick, N., Verma, I.M. (1995) Cellular and humoral
immune responses to adenoviral vectors containing factor IX gene: tolerization of both factor IX and vector
antigens allows for long term expression. Proceedings of the National. Academy of. Sciences. (USA),
92(5):1401-1405.
44. Geiger, K., Gurushanthaiah, D., Howes, E., Lewandowski, G., Bloom, F.E., Sarvetnick, N. (1995) Cytokine-
mediated survival from lethal HSV-infection: role of programmed neuronal death. Proceedings of the National
Academy of Sciences (USA), 92(8):3411-3415.
45. Lee, M.S., Gu, D-L., Feng, L., Curriden, S., Arnush, M., Krahl, T., Gurushanthaiah, D., Wilson, C.B., Loskutoff,
D.L., Fox, H., Sarvetnick, N. (1995) Accumulation of extracellular matrix and developmental dysregulation
in the pancreas by transgenic production of TGF-1. American Journal of Pathology, 147:42-52.
46. Gu, D-L., O'Reilly, L.A., Molony, L., Cooke, A., Sarvetnick, N. (1995) The role of infiltrating macrophages in
islet destruction and regrowth in a transgenic model. Journal of Autoimmunity, 8(4):483-492.
47. Geiger, K., Lee, M-S., Baugh, C., Sarvetnick, N. (1995) Protective effects of IFN- in intraocular HSV-1
infection do not depend on MHC class I or class II expression. Journal of Neurovirology, 1(5-6):405-409.
48. Gu, D-L., Molony, L., Krahl, T., Sarvetnick, N. (1995) Treatment of IFN- transgenic mice with anti-IFN-
reveals the remodeling capacity of the adult pancreas. Diabetes, 44(10):1161-1164.
49. Gu, D-L., Arnush, M., Sawyer, S.P., Sarvetnick, N. (1995) Transgenic mice expressing IFN- in pancreatic
beta-cells are resistant to streptozotocin induced diabetes. American Journal of Physiology, 269:1089-1094.
50. Geiger, K, Sarvetnick, N. (1995) The Influence of Cytokines on the Central Nervous System of Transgenic
Mice. Transgenic Models of Human Viral and Immunological Diseases: Vol.: Curr. Topics Microbio. &
Immunol. (FV Chaser & MBA Oldstone, Eds.) Springier Overflag, Germany, pp.101-117.
51. Balasa, B., Sarvetnick, N. (1996) The paradoxical effects of interleukin-10 in the immunoregulation of
autoimmune diabetes. Journal of. Autoimmunity, 9(2):283-286.
52. Geiger, K.D., Sarvetnick, N. (1996) Transgenic Expression of IFN- in the Eye as a Model for Studying Ocular
Inflammatory Disease. Methods. 10(3):392-405.
53. Gianani, R., Sarvetnick, N. (1996) Viruses, cytokines, antigens and autoimmunity. Proceedings of National
Academy of Sciences, (USA), 93(6):2257-2259.
54. Jones, E., Sarvetnick, N. (1996) Transgenic Animal Models: Insights into the regulation and maintenance of
islet cell mass. Diabetes Reviews, 4: 264-273.
55. Lee, M.S., Sawyer, S., Arnush, M., Krahl, T., von Herrath, M., Oldstone, M.A., Sarvetnick, N. (1996) TGF-
fails to inhibit allograft rejection or virus-induced autoimmune diabetes in transgenic mice. Transplantation,
61(7):1112-1115.
56. Mueller, R., Lee, M.S., Sawyer, S.P., Sarvetnick, N. (1996) Transgenic expression of interleukin-10 in the
pancreas renders resistant mice susceptible to low dose streptozotocin-induced diabetes. Journal of
Autoimmunity, 9(2):151-158.
57. Arnush, M., Gu, D-L., Baugh, C., Sawyer, S.P., Mroczkowski, B., Krahl, T., Sarvetnick, N. (1996) Growth
factors in the regenerating pancreas of gamma-interferon transgenic mice. Laboratory Investigation.
74(6):985-990.
58. Lee, M-S., Mueller, R., Wicker, L.S., Peterson, L.B., Sarvetnick, N. (1996) IL-10 is necessary and sufficient
for autoimmune diabetes in conjunction with NOD MHC homozygosity. Journal of Experimental Medicine,
183(6):2663-2668.
59. Morgan, D.J., Liblau, R., Scott, B., Fleck, S., McDevitt, J.O., Sarvetnick, N., Lo, D., Sherman, L.A. (1996)
CD8+ T cell-mediated spontaneous diabetes in neonatal mice. Journal of Immunology 157(3):978-983.
60. Mueller, R., Krahl, T., Sarvetnick, N. (1996) Pancreatic expression of interleukin-4 abrogates insulitis and
autoimmune diabetes in nonobese diabetic (NOD) mice. Journal of Experimental Medicine, 184(3):1093-
1100.
61. Geiger, K.D., Sarvetnick, N. (1996) Ocular production of interferon-gamma and lack of major
histocompatibility complex molecules induce immunological changes in the intraocular environment. German
Journal of Ophthalmology, 5(6):309-314.
62. Sarvetnick, N. (1996) Mechanisms of cytokine-mediated localized immunoprotection. Journal of
Experimental Medicine, 184(5):1597-1600.
63. Tian, J., Clare-Salzler, M., Herschenfeld, A., Middleton, B., Newman, D., Mueller, R., Arita, S., Evans, C.,
Atkinson, M.A., Mullen, Y., Sarvetnick, N., Tobin, A.J., Lehmann, P.V., Kaufman, D.L. (1996) Modulating
autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-
prone mice. Nature Medicine, 2(12):1348-1353.
64. Lee M-S, Sarvetnick, N., (1996) Cytokine Transgenic Mice and Autoimmunity In: Genetic Models of Immune
and Inflammatory Diseases Proceedings from Serena Symposia-Savannah GA, Springer-Verlag New York,
Inc. (Abul K. Abbas & Richard A. Flavell Eds.) pp.121-128.
65. Geiger, K, Bloom, FE, Sarvetnick, N. (1996) Apoptosis Techniques and Protocols In: Neuromethods. The
Humana Press Inc. (A.A. Boulton, G.B. Baker, and Judes Poirier, Eds.). pp. 217-235.
66. Geiger, KD, Sarvetnick, N. (1996) Transgenic expression of IFN- in the eye as a model to study ocular
inflammatory disease. NeuroProtocols (Iain Campbell, Ed.) Academic Press, San Diego, CA. pp. 392-405.
67. Allison, J, Miller, J, Sarvetnick, N., (1996) Insulin dependent diabetes mellitus.Role of Cytokines in
Autoimunity (M. Feldmann and F.M Brennan, Eds.) R.G. Landes Publishing Company, Austin, TX. pp. 49-75.
68. Horwitz, M, Sarvetnick, N. (1996) Viruses and Autoimmunity ANNALES DE L'INSTITUT
PASTEUR\actualités. (Ed. GN Cohen) Elsevier press; France. p.81.
69. Sarvetnick, N. (1997) IFN- IGIF, and IDDM. Journal of Clinical Investigation, 99(3):371-372.
70. Lee, M-S., Sarvetnick, N. (1997) Fetal exposure to interferon- leads to induction of antigen-presenting
molecules and leukocyte recruitment. Autoimmunity, 25(3):147-155.
71. Lee, M-S., Wicker, L.S., Peterson, L.B., Sarvetnick, N. (1997) Pancreatic IL-10 induces diabetes in NOD-
B6-Idd3-Idd10 mice. Autoimmunity, 26(4):215-221.
72. Mueller, R., Krahl, T., Sarvetnick, N. (1997) Tissue-specific expression of IL-4 induces extracellular matrix
accumulation and extravasation of B cells. Laboratory Investigation, 76(1):117-128.
73. Gu D-L., Arnush, M., Sarvetnick, N. (1997) Endocrine-exocrine intermediate cells in STZ treated Ins-IFN
transgenic mice. Pancreas, 15:246-250.
74. O'Reilly, L.A., Gu, D., Sarvetnick, N., Edlund, H., Phillips, J.M., Fulfort, T., Cooke, A. (1997) Alpha cell
neogenesis in an animal model of IDDM. Diabetes, 46(4):599-606.
75. Balasa, B., Deng, C., Lee, J., Bradley, L.M., Christadoss, P., Sarvetnick, N. (1997) IFN- is necessary for the
genesis of acetylcholine receptor-induced clinical experimental autoimmune Myasthenia Gravis in mice.
Journal of Experimental Medicine, 186(3):385-391.
76. Balasa, B., Krahl, T., Patstone, G., Lee, J., Tisch, R., McDevitt, H.O., Sarvetnick, N. (1997) CD40 ligand-
CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. Journal
of Immunology, 159(9):4620-4627.
77. Shaw, M.K., Lorens, J.B., Dhawan, A., DalCanto, R., Tse, H.Y., Tran, A.B., Bonpane, C., Eswaran, S.L.,
Brocke, S., Sarvetnick, N., Steinman, L., Nolan, G.P., Fathman, C.G. (1997) Local delivery of interleukin-4
by retrovirus-transduced lymphocytes ameliorates experimental autoimmune encephalomyelitis. Journal of
Experimental Medicine, 185(9):1711-1712.
78. Mueller, R., Davies, J.D., Krahl, T., Sarvetnick, N. (1997) Interleukin-4 expression by grafts from transgenic
mice fails to prevent allograft rejection. Journal of Immunology, 159(4):1599-1603.
79. Jones, E.M., Sarvetnick, N. (1997) Islet regeneration in IFN- transgenic mice. Hormone and Metabolic
Research, 29(6):308-310.
80. Mueller, R., Bradley, L.M., Krahl, T., Sarvetnick, N. (1997) Mechanism underlying counter-regulation of
autoimmune diabetes by IL-4. Immunity, 7(3):411-418.
81. Ohasi, P.S., Sarvetnick, N. (1997) Autoimmunity a bias from tolerance to immunity. Current Opinion in
Immunology, 9(6) 815-817.
82. Geiger, K.D., Nash, T.C., Sawyer, S., Krahl, T., Patstone, G., Reed, J.C., Krajewski, S., Dalton, D.,
Buchmeier, M.J., Sarvetnick, N. (1997) Interferon-gamma protects neurons against herpes simplex virus
type-1 mediated neuronal death. Virology 238(2):189-197.
83. Jones, EM, Sarvetnick, N. (1997) Balance between autoimmune destruction and regeneration: dual activities
of IFN-g in wound healing and inflammation. Pancreatic Growth and Regeneration, (Sarvetnick, N. ed.). RG
Landes Company, Georgetown TX. pp.108-114.
84. Krakowski, M, Sarvetnick, N. (1997) Perspectives in Pancreatic Development. Pancreatic Growth and
Regeneration. (Sarvetnick, N. ed.). R.G. Landes Company, Georgetown TX. Pages X-XI.
85. Sarvetnick, N. (1997) Edited Pancreatic Growth and Regeneration. RG Landes Company, Georgetown TX.
86. King, C., Sarvetnick, N. (1997) Organ-Specific autoimmunity. Current Opinion in Immunology, 9(6):863-871.
87. Falcone, M, Sarvetnick, N. (1997), “Transgenic models in autoimmunity.” Immunologically mediated
endocrine diseases. R. Gill et al. Lippincott-Reven.
88. Balasa, B., Sarvetnick, N. (1998) Cytokines and Insulin-Dependent Diabetes Mellitus: Implications for
Etiology and Therapy. Drug News & Perspectives, 11:356-360.
89. King, C., Davies, J., Mueller, R., Lee, M., Krahl, T., Yeung, B., O'Connor, E., Sarvetnick, N. (1998) TGF-1
alters APC preference, polarizing islet antigen response to Th2 phenotype. Immunity, 8(5):601-613.
90. Falcone, M., Lee, J., Patstone, G., Yeung, B., Sarvetnick, N. (1998) B lymphocytes are crucial antigen-
presenting cells in the pathogenic autoimmune response to GAD65 antigen in non-obese diabetic (NOD)
mice. Journal of Immunology, 161(3):1163-1168.
91. Horwitz, M. S., Bradley, L.M., Harbertson, J., Krahl, T., Lee, J., Sarvetnick, N. (1998) Diabetes induced by
Coxsackie virus: Initiation by bystander damage and not molecular mimicry. Nature Medicine, 4(7):781-785.
92. Balasa, B., Deng, C., Lee, J., Christadoss, P., Sarvetnick, N. (1998) The Th2 cytokine IL-4 is not required
for the progression of antibody-dependent autoimmune myasthenia gravis. Journal of Immunology,
161(6):2856-2862.
93. Balasa, B., Davies, J. D., Lee, J., Good, A., Yeung, B., Sarvetnick, N. (1998) Interleukin-10 impacts
autoimmune diabetes via a CD8+ T cell pathway circumventing the requirement for CD4+ T- and B-
lymphocytes. Journal of Immunology, 161(8):4420-4427.
94. Kafri T., Morgan, D., Krahl, T., Sarvetnick, N., Sherman, L., Verma I. (1998) Cellular immune response to
adenoviral vector infected cells does not require De Novo viral gene expression: implications for gene therapy.
Proceedings of National Academy of Sciences (USA), 95(19):11377-11382.
95. Gallichan, W.S., Kafri, T., Krahl, T., Verma, I.M., Sarvetnick, N. (1998) Lentivirus-mediated transduction of
islet grafts with IL-4 results in sustained gene expression and protection from insulitis. Human Gene Therapy,
9(18):2717-2726.
96. Horwitz, M.S., Krahl, T., Fine, C., Lee, J., Sarvetnick N. (1999) Protection from lethal coxsackie virus-induced
pancreatitis by expression of gamma interferon. Journal of. Virology, 73(3):1756-1766.
97. Falcone, M., Sarvetnick, N. (1999) Cytokines that regulate autoimmune responses. Current Opinion in.
Immunology, 11(6):670-676.
98. Falcone, M, Sarvetnick, N. (1999) The Effect of local production of cytokines in the pathogenesis of insulin-
dependent diabetes mellitus. Clinical Immunology, 90(1):2-9.
99. Bradley, L.M., Asensio, V.C., Schioetz, L-K, Harbertson, J., Krahl, T., Patstone, G., Woolf, N., Campbell, I.L.,
Sarvetnick, N. (1999) Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid
induction of autoimmune diabetes. Journal of Immunology, 162(5):2511-2520.
100. Horwitz, M.S., Sarvetnick, N. (1999) Viruses, host responses, and autoimmunity Immunological Reviews,
169:241-253.
101. Balasa, B. Sarvetnick, N. (1999) Is pathogenic humoral autoimmunity a Th1 response Lessons from
myasthenia gravis. Immunology Today, 21(1):19-23.
102. Krakowski, M.L., Kritzik, M.R., Jones, E.M., Krahl, T., Lee, M. Arnush, M. Gu, D. Mroczkowski, B.,
Sarvetnick, N. (1999) Transgenic expression of EGF and KGF in beta-cells results in substantial
morphological changes. Journal of Endocrinology, 162(2):167-175.
103. Shelton, G.D., Calcutt, N.A., Garrett, R.S., Gu, D., Sarvetnick, N., Campana, W.M., Powell, H.C. (1999)
Necrotizing myopathy induced by overexpression of interferon-gamma in transgenic mice. Muscle Nerve
22(2):156-165.
104. Wogensen, L., Nielsen, C.B., Hjorth, P., Rasmussen, L.M., Nielsen, A.H., Gross, K., Sarvetnick, N., Ledet,
T. (1999) Under control of the Ren-1c promoter, locally produced transforming growth factor-1 induces
accumulation of glomerular extracellular matrix in transgenic mice. Diabetes, 48(1):182-192.
105. Krakowski, M.L., Kritzik, M.R., Jones, E.M., Krahl, T., Lee, J., Arnush, M., Gu, D., Sarvetnick, N. (1999)
Pancreatic expression of keratinocyte growth factor leads to differentiation of islet hepatocytes and
proliferation of duct cells. American Journal of Pathology, 154(3):683-691.
106. La Cava, A, Sarvetnick, N., (1999) The role of cytokines in autoimmune diseases. Current Directions in
Autoimmunity. (Theofilopoulas, ed.). S. Karger AG, Basel, Witzerland. pp.56-71.
107. Davies, J.D., Mueller, R., Minson, S., O'Connor, E., Krahl, T., Sarvetnick, N. (1999) Interleukin-4 secretion
by the allograft fails to affect the allograft-specific interleukin-4 response in vitro. Transplantation,
67(12):1583-1589.
108. Balasa, B., Lee, J., Sarvetnick. N. (1999) Differential impact of T cell repertoire diversity in diabetes-prone
or -resistant IL-10 transgenic mice. Cellular Immunology, 193(2):170-178.
109. Falcone, M., Yeung, B., Tucker, L., Rodriguez, E., Sarvetnick, N. (1999) A defect in IL-12 induced activation
and IFN- secretion of peripheral NKT cells in NOD mice suggest new pathogenic mechanisms for IDDM.
Journal of Experimental Medicine, 190(7):963-972.
110. Gallichan, W.S., Balasa, B., Davies, J.D., Sarvetnick, N. (1999) Pancreatic IL-4 expression results in islet-
reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. Journal of
Immunology. 163(6):1696-1703.
111. Kritzik, M.R., Jones, E.M., Chen, Z., Krakowski, M., Krahl, T., Good, A., Wright, C., Fox, H., Sarvetnick, N.
(1999) PDX-1 and MSX-2 expression in the regenerating and developing pancreas. Journal of Endocrinology,
163(3):523-530.
112. Davies, J.D., O’Connor, E., Hall, D., Krahl, T., Trotter, J. Sarvetnick, N. (1999) CD4 CD45RB low-density
cells from untreated mice prevent acute allograft rejection. Journal of Immunology, 163(10):5353-5357.
113. Kreuwel, H., Morgan, D.J., Krahl, T., Ko, A., Sarvetnick, N., Sherman, L.A. (1999) Comparing the relative
role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-
dependent diabetes mellitus. Journal of Immunology, 163(8):4335-4341.
114. Kritzik, M.R., Krahl, T., Good, A., Gu, D., Lai, C., Fox, H., Sarvetnick, N. (2000) Expression of ErbB receptors
during pancreatic islet development and regrowth. Journal of Endocrinology, 165(1):67-77.
115. Kritzik, M.R., Krahl, T., Good, A., Krakowski, M. St.-Onge, L., Gruss, P., Wright, C., Sarvetnick, N. (2000)
Transcription Factor Expression During Pancreatic Islet Regeneration. Molecular Cellular Endocrinology,
164(1-2):99-107.
116. Balasa, B., Van Gunst, K., Sarvetnick, N. (2000) The microbial product lipopolysaccharide confers
diabetogenic potential on the T cell repertoire of BDC2.5/NOD mice: implications for the etiology of
autoimmune diabetes. Clinical Immunology, 95(2):93-98.
117. Horwitz, M.S., La Cava, A., Fine, C., Rodriguez, E., Ilic, A., Sarvetnick, N. (2000) Pancreatic expression of
interferon- protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nature
Medicine, 6(6):693-697.
118. Krakowski, M., Yeung, B., Abdelmalik, R., Good, A., Mocnik, L., Sosa-Pineda, B., St-Onge, L., Gruss, P.
Sarvetnick, N. (2000) IFN- overexpression within the pancreas is not sufficient to rescue Pax4, Pax6 and
Pdx-1 mutant mice from death. Pancreas, 21(4):399-406.
119. Balasa, B., Van Gunst, K., Jung, N., Katz, J.D. Sarvetnick, N. (2000) IL-10-Deficiency does not inhibit
insulitis and accelerates cyclophosphamide-induced diabetes in the nonobese diabetic (NOD) mouse.
Cellular Immunology, 202(2):97-102.
120. Sarvetnick, N. (2000) Etiology of Autoimmunity. Immunologic Research, The Humana Press Inc. 21(2-
3):357-362.
121. Balasa, B., Van Gunst, K., Jung, N., Balakrishna, D., Santamaria, P., Hanafusa, T., Itoh, N., Sarvetnick, N.
(2000) Islet-specific expression of interleukin-10 promotes diabetes in nonobese diabetic (NOD) mice
independent of Fas, Perforin, TNFR-1 and TNFR-2 molecules. Journal of Immunology, 165(5):2841-2849.
122. Shi, F-D, Takeda, K., Akira, S., Sarvetnick, N., Ljunggren, H-G (2000) IL-18 directs autoreactive T cells and
promotes autodestruction in the central nervous system via induction of IFN- by NK cells. Journal of.
Immunology, 165(6):3099-3104.
123. Balasa, B., La Cava, A., Van Gunst, K., Mocnik, L., Balakrishna, D., Nguyen, N., Tucker, L., Sarvetnick, N.
(2000) A mechanism for IL-10-mediated diabetes in the nonobese diabetic (NOD) mouse: ICAM-1 deficiency
blocks accelerated diabetes. Journal of Immunology, 165(12):7330-7337.
124. Balsa B, Sarvetnick N. 2000, Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for)
myasthenia gravis. Immunology Today, 21 (1) 19-23.
125. Falcone, M., Yeung, B., Tucker, L., Rodriguez, E., Krahl, T., Sarvetnick, N. (2001) IL-4 Triggers autoimmune
diabetes by increasing self-antigen presentation within the pancreatic islets. Clinical Immunology, 98(2):190-
199.
126. King, C., Mueller-Hoenger, R.M., Malo-Cleary, M., Murali-Krishna, K., Ahmed, R., King, E., Sarvetnick, N.
(2001) Interleukin-4 acts at the locus of the antigen-presenting dendritic cell (APC) to counter-regulate
cytotoxic CD8+ T cell responses. Nature Medicine, 7(2):206-214.
127. Flodstrom, M., Horwitz, M.S., Maday, A., Balakrishna, D., Rodriguez, E., Sarvetnick, N. (2001) A critical role
for inducible nitric oxide synthase (NOS2) in host survival following coxsackievirus B4 infection. Virology,
281(2):205-215.
128. Balasa, B., Boehm, B.O., Fortnagel, A., Karges, W., Van Gunst, K., Jung, N., Camacho, S.A., Webb, S.R.
Sarvetnick, N. (2001) Vaccination with glutamic acid decarboxylase (GAD) plasmid DNA protects mice from
spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection. Clinical
Immunology, 99(2):241-252.
129. Liu, G., Pakala, S.V., Gu, D., Krahl, T., Mocnik, L., Sarvetnick, N. (2001) Cholecystokinin expression in the
developing and regenerating pancreas and intestine. Journal of Endocrinology, 169(2):233-240.
130. Pakala, S., Ilic, A., Chen, L., Sarvetnick, N. (2001) TNF- receptor 1 (p55) on islets is necessary for the
expression of LIGHT on diabetogenic T cells. Clinical Immunology, 100(2):198-207.
131. La Cava, A., Balasa, B., Good, A., Van Gunst, K., Jung, N., and Sarvetnick, N. (2001) H-2D end confers
dominant protection from IL-10-mediated acceleration of autoimmune diabetes in the nonobese diabetic
(NOD) mouse. Journal of Immunology, 167(2):1066-1071.
132. Shi, F-D, Flodstrom, M., Balasa, B., Kim, S-H., Van Gunst, K., Strominger, J.L., Wilson, S.B., Sarvetnick, N.
(2001) Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proceedings of National
Academy of Sciences, USA, 98(12):6777-6782.
133. Shi, F-D., Ljunggren, H-G., Sarvetnick, N. (2001) Innate immunity and autoimmunity: From self-protection
to self-destruction. Trends in Immunology, 22(2):97-101.
134. Shi, F-D, Flodstrom, M., Kim, S.H., Pakala, S., Cleary, M., Ljunggren, H-G., Sarvetnick, N. (2001) Control
of the autoimmune response by type 2 nitric oxide synthase. Journal of Immunology, 167(5):3000-3006.
135. Horwitz, M.S., Fine, C., Ilic, A., Sarvetnick, N. (2001) Requirements for viral-mediated autoimmune diabetes:
beta-cell damage and immune infiltration. Journal of Autoimmunity, (16(3):211-217.
136. Kritzik, M, Sarvetnick, N. (2001) Pancreatic Stem Cells. Stem Cell Biology, (Eds. D Marshak, RL Gardner,
D Gottlieb) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp.499-513.
137. Shi, F-D, Sarvetnick, N. (2001) Regulation of autoreactive T cells in myasthenia gravis. Inflammatory Events
in Neurodegeneration, (Bondy & Campbell eds.), Prominent Press, pp.292-307.
138. Camacho, S.A., Heath, W.R., Carbone, F.R., Sarvetnick, N., Lebon, A., Karlsson, L., Peterson, P.A., Webb,
S.A. (2001) A key role for ICAM-1 in generating effector cells mediating inflammatory responses. Nature
Immunology, 2(6):523-529.
139. Judkowski, V., Pinilla, C., Schroder, K., Tucker, L., Sarvetnick, N., Wilson, D.B., (2001) Identification of MHC
class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate
diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. Journal of Immunology. 166(2):908-
917.
140. Kaufman, D.L., Tisch, R., Sarvetnick, N., Chatenoud, L., Harrison, L.C., Haskins, K., Quinn, A., Sercarz, E.,
Singh, B., von Herrath, M., Wegmann, D., Wen, L., Zekzer, D. (2001) Report from the 1st International NOD
Mouse T-Cell Workshop and the follow-up mini-workshop. Diabetes, 50(11):2459-2463.
141. Flodstrom, M., Shi, FD, Sarvetnick, N., Ljunggren, H.G. (2002) The natural killer cell -- friend or foe in
autoimmune disease? Scandinavian Journal of Immunology. 55(5):432-441.
142. Krakowski, M., Abdelmalik, R., Mocnik, L., Krahl, T., Sarvetnick, N. (2002) Granulocyte macrophage-colony
stimulating factor (GM-CSF) recruits immune cells to the pancreas and delays STZ-induced diabetes. Journal
of Pathology, 196(1):103-112.
143. Horwitz, M., Ilic, A., Fine, C., Rodriguez, E., Sarvetnick, N. (2002) Presented antigen from damaged
pancreatic cells activates autoreactive T cells in virus-mediated autoimmune diabetes. Journal of Clinical
Investigation, 109(1):79-87.
144. Flodstrom, M., Maday, A., Balakrishna, D., Cleary, M., Yoshimura, A., Sarvetnick, N. (2002) Target cell
defense prevents the development of diabetes after viral infection. Nature Immunology, 3(4):373-382.
145. Hill, N., Sarvetnick, N. (2002) Cytokines: promoters and dampeners of autoimmunity. Current Opinion in
Immunology, 14(6):791-797.
146. Matarese, G., Sanna, V., Lechler, R.I., Sarvetnick, N., Fontana, S., Zappacosta, S., La Cava, A. (2002)
Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes; 51(5):1356-1361.
147. Kim, S-H., Cleary, M.M. Fox, H.S., Chantry, D., Sarvetnick, N. (2002) CCR4 bearing T cells participate in
autoimmune diabetes. Journal of Clinical Investigation, 110(11):1675-1686.
148. Horwitz, M, Sarvetnick, N. (2002) “Coxsackievirus.” Wiley Encyclopedia of Molecular Medicine, 5 Vol. Set,
John Wiley & Sons, Inc., pp.924-926.
149. Hill, N., Van Gunst, K., Sarvetnick, N. (2003) Th1 and Th2 pancreatic inflammation differentially affects
homing of islet-reactive CD4 cells in non-obese diabetic (NOD) mice. Journal of Immunology, 170(4):1649-
1658.
150. Flodstrom, M., Tsai, D., Fine, C., Maday, A., Sarvetnick, N. (2003) Diabetogenic potential of human
pathogens uncovered in experimentally permissive beta-cells. Diabetes, 52(8):2025-2034.
151. Horwitz, M., Ilic, A., Fine, C., Rodriguez, E., Sarvetnick, N. (2003) Coxsackievirus-mediated hyperglycemia
is enhanced by reinfection and this occurs independent of T cells. Virology, 314(2):510-20.
152. Flodstrom,-Tullberg, M., Yadav, D., Hagerkvist, R., Tsai, D., Secrest, P., Stotland, A., Sarvetnick, N. (2003)
Target cell expression of suppressor of cytokine signaling-1 (SOCS-1) prevents diabetes in the NOD mouse.
Diabetes, 52(11):2696-2700.
153. Kayali, A., Van Gunst, K., Campbell, L., Stotland, A., Kritzik, M., Liu, G., Flodstrom-Tullberg, M., Zhang, Y-
Q., Sarvetnick, N. (2003) The stromal cell-derived factore-1/ CXCR4 ligand-receptor axis is critical for
progenitor survival and migration in the pancreas. Journal of Cell Biology, 163(4):859-869.
154. Sarvetnick, N., Ohashi, P. (2003) Autoimmunity. Current Opinions in Immunology, 15(6):647-650.
155. Yadav, D., Sarvetnick, N. (2003) Cytokines and autoimmunity: redundancy defines their complex nature.
Current Opinion in Immunology, 15(6):697-703.
156. Zhang, Y-Q., Sarvetnick, N. (2003) Development of cell markers for the identification and expansion of islet
progenitor cells. Diabetes Metabolism Research and Review, 19(5):363-374.
157. Horwitz, M., Ilic, A., Fine, C. Balasa, B., Sarvetnick, N. (2004) Coxsackieviral-mediated diabetes: Induction
requires antigen presenting cells and is accompanied by phagocytosis of beta cells. Clinical Immunology,
110(2):134-144.
158. Jie, H-B., Sarvetnick, N. (2004) The role of NK cells and NK cell receptors in autoimmune disease.
Autoimmunity, 37(2):147-153.
159. Judkowski, V., Pinilla, C., Alicotti, G., Flodstrom, M., Sanna, P., Sarvetnick, N. (2004) Strong attraction may
be dangerous: parameters for the development of long term commitment. Molecular Immunology, 40(14-
15):1109-1112.
160. Judkowski, V., Krakowski, M., Rodriguez, E., Mocnick, L., Santamaria, P., Sarvetnick, N. (2004) Increased
islet antigen presentation leads to type-1 diabetes in mice with autoimmune susceptibility. European Journal
Immunology, 34(4):1031-1040.
161. Judkowski, V., Rodriguez, E., Pinilla, C., Masteller, E., Bluestone, J., Sarvetnick, N., Wilson, D. (2004)
Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes. Clinical Immunology,
113:29-37.
162. King, C, Ilic, A, Koelsch, K, Sarvetnick, N. (2004) Homeostatic expansion of T cells dueing immune
insufficiency generates autoimmunity. Cell, 117(2):265-277.
163. Robey, IF, Peterson, M., Horwitz, MS., Kono, DH, Stratmann, T., Theofilopoulos, AN., Sarvetnick, N.,
Teyton, L., Feeney, AJ. (2004) Terminal Deoxynucleotidyl Transferase Deficiency Decreases Autoimmune
Disease in Diabetes-prone NOD Mice and Lupus-prone MRL-Fas (lpr) Mice. Journal of Immunology.
172(7):4624-4629.
164. Zhang, Y-Q., Cleary, M., Si, Y., Liu, G., Eto, Y., Kritzik, M., Dabernat, S., Kayali, A., Sarvetnick, N. (2004)
Inhibition of activin signaling induces pancreatic epithelial cell expansion and diminishes terminal
differentiation of pancreatic beta-cells. Diabetes, 53(8):2024-2033.
165. Judkowski, V, Allicotti, GM., Sarvetnick, N., Pinilla, C. (2004) Peptides from common viral and bacterial
pathogens can efficiently activate diabetogenic T cells. Diabetes, 53(9):2301-2309.
166. Falcone M., Facciotti F., Ghidoli N., Monti P., Olivieri S., Zaccagnino L., Bonifacio, E., Casorati, G., Sanvito,
F., Sarvetnick N. (2004) Up-regulation of CD1d expression restores the immunoregulatory function of NKT
cells and prevents autoimmune diabetes in non-obese diabetic mice. Journal of Immunology, 172(10):5908-
5916.
167. Solomon, M, Sarvetnick, N. (2004) The pathogenesis of diabetes in the NOD mouse. Advances in
Immunology, 84:239-264.
168. Yadav, D., Judkowski, V., Flodstrom, M., Sterling, L., Redmond, W., Sherman, L., Sarvetnick, N. (2004) B7-
2 (CD86) controls the priming phase of autoreactive CD4 T cell response against pancreatic islets. Journal
of Immunology, 173(6):3631-3639.
169. Flodstrom-Tullberg, M., Hultcrantz, M., Stotand, A., Maday, A., Tsai, D., Fine, C., Williams, B., Silverman, R.,
Sarvetnick, N. (2005) RNase L and Double-Stranded RNA-Dependent Protein Kinase Exert Complementary
Roles in Islet Cell Defense during Coxsackievirus Infection. Journal of Immunology, 174(3):1171-1177.
170. Marleau, A., Sarvetnick, N. (2005) T Cell Homeostasis in Tolerance and Immunity. Journal of Leukocyte
Biology. 78(3):575-584.
171. Solomon, M., Flodstrom-Tullberg, M., Sarvetnick, N. (2005) Differences in Suppressor of Cytokine
Signaling-1 (SOCS-1) Expressing Islet Allograft Destruction in Normal BALB/c and Spontaneously Diabetic
NOD Recipient Mice. Transplantation, 79(9):1104-1109.
172. Kayali A.G., Stotland A., Gunst K.V., Kritzik M., Liu, Guoxun., Dabernat S., Zhang Y-Q., Sarvetnick N. (2005)
Growth Factor Induced Signaling of the Pancreatic Epithelium, Journal of Endocrinology, 185:45-56.
173. Zhang Y-Q., Kritzik M., Sarvetnick N. (2005) Identification and Expansion of Pancreatic Stem/Progenitor
Cells, Journal of Cellular Molecular Medicine, 90(2):331-344.
174. Horwitz M.S., Ilic A., Fine C., Sarvetnick N. (2005) Induction of Antigen Specific Peripheral Humoral
Tolerance to Cardiac Myosin Does Not Prevent CB3-mediated Autoimune Myocarditis. Journal of
Autoimmunity, 25(2):102-11.
175. Martinez X., Kreuwel HT., Redmond WL., Trenney R, Hunter K., Rosen H, Sarvetnick N., Wicker, LS.,
Sherman LA. (2005) CD8+ T cell tolerance in nonobese diabetic mice is restored by insulin-dependent
diabetes resistance alleles. Journal of Immunology, 175(3):1677-85.
176. Kim SH., Gunst KV, Sarvetnick, N. (2006) STAT4/6-dependent differential regulation of chemokine
receptors. Clinical Immunology, 118: 250-257.
177. Hua H., Zhang YQ., Arnaud-Dabernat S., Krtizik M., Dietz D., Sterling L, Sarvetnick N. (2006) BMP4
regulates pancreatic progenitor cell expansion through ID2. Journal of Biological Chemistry, 281:13574.
178. Yadav D., and Sarvetnick N. (2006) Co-stimulation and pancreatic autoimmunity: the PD-1/PD-L
conundrum. Review of Diabetic Studies, 3: 6-10.
179. Liu G., Dabernat-Arnaud S., Kritzik M.R., Kayali A.G., Zhang Y-Q., Sarvetnick N. (2006) PYY in the
expanding pancreatic epithelium. Endocrine, 30:103-112.
180. Horwitz M.S., Knudsen M., Ilic A., Fine C., Sarvetnick N. (2006) TGF-beta inhibits Coxsackievirus-mediated
autoimmune myocarditis. Viral Immunology 19: 722-733.
181. Arnaud-Dabernat S, Kritzik M., Kayali A.G., Zhang Y.-Q, Liu G., Ungles C., and Sarvetnick N. (2007) FGFR
is a negative regulator of the expansion of pancreatic epithelial cells. Diabetes, 56:96-106.
182. Yadav D., Fine C., Azuma M., and Sarvetnick N. (2007) B7-1 mediated co-stimulation regulates pancreatic
autoimmunity. Molecular Immunology 44: 2616-2624.
183. Yadav D., and Sarvetnick N. (2007) Immunomodulation of the anti-islet CD8 T cell response by B7- 2,
Journal of Clinical Immunology 27:221-226.
184. Hill N.J., Hulcrantz M., Sarvetnick N., and Flodstrom-Tullberg M. (2007) The target tissue in autoimmunity
– an influential niche. European Journal of Immunology 37: 589-597.
185. Hill N.J., Stotland A.B., and Sarvetnick N. (2007) Distinct regulation of autoreactie CD4 T cell expansion by
interleukin-4 under conditions of lymphopenia. Journal of Leukocyte Biology, 81: 757-765.
186. Hill N.J., Stotland A.B., Solomon M., Secrest P., Getzoff E., and Sarvetnick N. (2007) Resistance of the
target islet tissue to autoimmune destruction contributes to genetic susceptibility in Type 1 diabetes. Biology
Direct, 2: 5.
187. Yadav D, and Sarvetnick N. (2007) B7-2 regulates survival, phenotype and function of antigen presenting
cells. Journal of Immunology, 178:6236-6241.
188. Arnaud-Dabernat S., and Sarvetnick N. (2007) Tyrosine kinase receptors are crucial for normal beta cell
development and function. Expert Review of Endocrinology & Metabolism 2(2): 175-183.
189. Hua, H and Sarvetnick, N. (2007) Id2 promotes the expansion and survival of growth-arrested pancreatic
Beta cells. Endocrine, 32: 329-337.
190. Hua H and Sarvetnick N. (2008) Expression of Id1 in Adult, Regenerating and Developing Pancreas.
Endocrine, 32: 280-286.
191. Zhang Y.-Q., Sterling L., Stotland A., Hua H., Kritzik M., and Sarvetnick N. (2008) Nodal and Lefty signaling
regulates the growth of pancreatic cells. Developmental Dynamics, 237: 1255-1267.
192. Datta S., Sarvetnick N. (2008) IL-21 limits peripheral lymphocyte numbers through T cell homeostatic
mechanisms. Plos One, 3 (9) e 3118.
193. Arnaud-Dabernat S., Yadav D., and Sarvetnick N. (2008) FGFR3 contributes to intestinal crypt cell growth
arrest. Journal of Cellular Physiology 21: 261-268.
194. Yadav D., Hill Yagita, H., Azuma M., and Sarvetnick N. (2009) Altered availability of PD-1PD ligands is
associated with the failure to control Autoimmunity in NOD Mice. Cellular Immunology, 258 (2): 161-171
195. Datta S. and Sarvetnick N. (2009) Lymphocyte proliferation in Immune mediated Diseases. Trends in
Immunology, 30(9):430-8.
196. Zhang Y., Resta S., Jung B., Barrett K., Sarvetnick N. (2009) Up-regulation of Activin Signaling in
Experimental Colitis. American Journal of Physiology, 297(4):G768-80.
197. Solomon M., Balasa B., Sarvetnick N. (2010) CCR2 and CCR5 Chemokine receptors differentially Influence
the Development of Autoimmune Diabetes in the NOD Mouse. Autoimmunity, 43(2):156-163.
198. Dabernat S., Secrest P., Peuchant E., Moreau-Gaudry F., Dubus P., Sarvetnick N. (2009) Lack of beta-
catenin in early life induces abnormal glucose homeostasis in mice. Diabetologia, (8): 1608-17.
199. Kritzik M, Lago C, Kayali A, Dabernat-Arnaud, S, Liu G, Zhang Y, Hua H, Fox H, Sarvetnick N, (2010)
Epithelial Progenitor-1 (EP-1) a Novel Factor Associated with Epithelial Cell Growth and Differentiation.
Endocrine, 37:312-321.
200. Solomon M, Flodstrom-Tullberg M, Sarvetnick N. (2011) Beta-Cell specific expression of suppressor of
cytokine signaling-1 (SOCS-1) delays islet allograft rejection by down-regulating Interferon Regulatory Factor-
1 (IRF-1) signaling. Transpl Immunol, 24:181-188.
201. King C, Sarvetnick N. (2011) The incidence of type-1 diabetes in NOD mice is modulated by restricted flora
not germ-free conditions. PloS One, 6:e17049.
202. Marleau AM, Sarvetnick NE, (2011) IL-18 is required for self-reactive T cells expansion in NOD mice. J
Autoimmunity, 36(3-4): 263-77.
203. Liu SM, Lee DH, Sullivan JM, Chung D, Jager A, Shum BO, Sarvetnick NE, Anderson AC, Kuchroo VK,
(2011) Differential IL-21 signaling in APCs leads to disparate Th17 differentiation in diabetes-susceptible NOD
and diabetes-resistant NOD.Idd3 mice. J Clin Invest, 121(11): 4303-10.
204. Boerner BP, Sarvetnick NE, (2011) Type 1 diabetes: role of intestinal microbiome in humans and mice. Ann
NY Acad Sci., 1243:103-18.
205. George NM, Day CE, Boerner BP, Johnson RL, Sarvetnick NE, (2012) Hippo signaling regulates pancreas
development through inactivation of Yap. Mol Cell Biol., 32(24):5116-28.
206. Harms R, Morsey B, Boyer C, Fox HS, Sarvetnick NE, (2012) Methamphetamine administration targets
multiple immune subsets and induces phenotypic alterations suggestive of immunosuppression. PLoS One.,
7(12):e49897. PMID: 23227154
207. Boerner B, George N, Targy N, Sarvetnick NE, (2013) TGF-Beta Superfamily Member Nodal Stimulates
Human Beta Cell Proliferation While Maintaining Cellular Viability. Endocrinology., epub. PMID: 23970788
208. Yarde DN, Lorenzo-Arteaga K, Corley KP, Cabrera M, Sarvetnick NE (2014) CD28- CD8+ T cells are
significantly reduced and correlate with disease duration in juveniles with Type I diabetes. Human
Immunology, pii: S0198-8859(14)00424-8. In Press.
209. Harms, R, Lorenzo-Arteaga K, Corley KP, Cabrera M, Sarvetnick NE (2014) Altered CD161bright CD8+
mucosal associated invariant T (MAIT)-like cell dynamics and increased differentiation states among juvenile
type 1 diabetics. PLoS One, In Press.
210. George N, Boerner B, Mir S, Sarvetnick NE, (2014) Exploiting expression of the Hippo effector, Yap, for
expansion of functional islet mass. Molecular Endocrinology, In Revision
211. Mir S, George N, Boerner B, Sarvetnick NE, (2014) Inhibition of autophagic turnover in Beta-Cells by fatty
acids and glucose leads to apoptotic cell death. Journal of Biological Chemistry, In Revision
212. George N, Boerner B, Mir S, Sarvetnick NE (2014) Hippo protector protein, Taz, regulates development of
pancreatic ducts. Mechanisms of Development, In Revision.
213. Boerner B, George N, Sarvetnick NE (2014) WS6 induces both alpha and beta cell proliferation without
affecting differentiation or viability. Journal of Endocrinology. Submitted.